Evidence map›Paper›PMID 41641990›Full record

ArticlemBio2026

Reduction of the HIV-1 reservoir in T cells from people with HIV-1 on suppressive antiretroviral therapy using expanded natural killer cells.

Mary Ann Checkley, Benjamin G Luttge, Cheryl M Cameron, Konstantin S Leskov, Curtis Dobrowolski, David N Wald, Deborah McMahon, Ghady Haidar, Michele D Sobolewski, P Nathan Enick and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mary Ann CheckleyDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0001-6931-4057
Benjamin G LuttgeDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-1296-8014
Cheryl M CameronDepartment of Nutrition, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Konstantin S LeskovDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Curtis DobrowolskiDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
David N WaldDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Deborah McMahonDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Ghady HaidarDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-0634-8211
Michele D SobolewskiDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
P Nathan EnickDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Joshua CyktorDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
John W MellorsDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-3737-9742
Jonathan KarnDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-2900-094X

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Immaculate Lillian Nankya · 1994 to 2026
$50.0M
CRISPR for CureUM1AI164568 · NIAID · TEMPLE UNIV OF THE COMMONWEALTH · PI Tricia Helen Burdo, Kamel Khalili · 2021 to 2026
$27.7M
Identification and eliminationof HIV reservoirs in oral lymphoid tissues by engineered NK cells.R01DE025464 · NIDCR · CASE WESTERN RESERVE UNIVERSITY · PI KARN, JONATHAN · 2015 to 2019
$3.8M
HIV eradication by ADCC-activated NK cell killingR33AI110156 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI KARN, JONATHAN · 2016 to 2018
$1.4M
NCI NIH HHS P30 CA043703NIAID NIH HHS P30 AI036219NIAID NIH HHS R33 AI110156NIAID NIH HHS UM1 AI164568NIDCR NIH HHS R01 DE025464
6 · The paper itself

Abstract

Treatment with latency-reversing agents (LRAs) alone has been ineffective in reducing HIV-1 reservoirs in people living with HIV-1 (PLWH) who are on antiretroviral therapy (ART), due to inefficiencies in reservoir reactivation and adaptive immune responses. However, NK cells activated with cytokines may be able to target HIV-1 reservoirs more effectively. To explore the therapeutic potential of NK cells, we expanded blood NK cells from multiple donors

Indexed as

Anti-Retroviral AgentsCD4-Positive T-LymphocytesHIV-1HIV InfectionsKiller Cells, NaturalAntibody-Dependent Cell CytotoxicityHIV AntibodiesHumansInterleukin-15Viral LoadVirus LatencyVorinostatAnti-Retroviral AgentsHIV AntibodiesInterleukin-15VorinostatADCCbroadly neutralizing antibodiesEDITS assayhuman immunodeficiency virusIntact proviral assaylatency-reversing agentsNK cellsshock and kill strategy

Identifiers

PMID41641990
PMCPMC12977593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.